相似文献
1
Repurposing an Antiviral Drug against SARS-CoV-2 Main Protease.
Angew Chem Int Ed Engl. 2021 Oct 25;60(44):23492-23494. doi: 10.1002/anie.202107481. Epub 2021 Sep 21.
2
X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease.
Science. 2021 May 7;372(6542):642-646. doi: 10.1126/science.abf7945. Epub 2021 Apr 2.
3
Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M Protease.
Molecules. 2020 Nov 6;25(21):5172. doi: 10.3390/molecules25215172.
4
Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
Bioorg Med Chem. 2021 Oct 1;47:116393. doi: 10.1016/j.bmc.2021.116393. Epub 2021 Sep 4.
5
Potential SARS-CoV-2 protease M inhibitors: repurposing FDA-approved drugs.
Phys Biol. 2021 Feb 9;18(2):025001. doi: 10.1088/1478-3975/abcb66.
6
Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication.
Nat Commun. 2020 Aug 27;11(1):4282. doi: 10.1038/s41467-020-18096-2.
7
Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CL).
J Med Chem. 2022 Feb 24;65(4):2880-2904. doi: 10.1021/acs.jmedchem.1c00598. Epub 2021 Aug 4.
8
Nonpeptidic Irreversible Inhibitors of SARS-CoV-2 Main Protease with Potent Antiviral Activity.
J Med Chem. 2024 Sep 12;67(17):14986-15011. doi: 10.1021/acs.jmedchem.4c00535. Epub 2024 Aug 15.
9
Uncovering Flexible Active Site Conformations of SARS-CoV-2 3CL Proteases through Protease Pharmacophore Clusters and COVID-19 Drug Repurposing.
ACS Nano. 2021 Jan 26;15(1):857-872. doi: 10.1021/acsnano.0c07383. Epub 2020 Dec 29.
10
Identification of non-covalent 3C-like protease inhibitors against severe acute respiratory syndrome coronavirus-2 via virtual screening of a Korean compound library.
Bioorg Med Chem Lett. 2021 Jun 15;42:128067. doi: 10.1016/j.bmcl.2021.128067. Epub 2021 May 3.
引用本文的文献
1
3-chymotrypsin-like protease in SARS-CoV-2.
Biosci Rep. 2024 Aug 28;44(8). doi: 10.1042/BSR20231395.
2
Advancements in Antiviral Drug Development: Comprehensive Insights into Design Strategies and Mechanisms Targeting Key Viral Proteins.
J Microbiol Biotechnol. 2024 Jul 28;34(7):1376-1384. doi: 10.4014/jmb.2403.03008. Epub 2024 Apr 29.
3
[Not Available].
Acta Pharm Sin B. 2024 Jan;14(1):87-109. doi: 10.1016/j.apsb.2023.08.004. Epub 2023 Aug 9.
4
Development of Masitinib Derivatives with Enhanced M Ligand Efficiency and Reduced Cytotoxicity.
Molecules. 2023 Sep 15;28(18):6643. doi: 10.3390/molecules28186643.
5
Indole-Based Compounds as Potential Drug Candidates for SARS-CoV-2.
Molecules. 2023 Sep 13;28(18):6603. doi: 10.3390/molecules28186603.
6
Electrochemical Biosensor for the Detection of SARS-CoV-2 Main Protease and Its Inhibitor Ebselen.
Int J Electrochem Sci. 2022 Apr;17(4):220421. doi: 10.20964/2022.04.19. Epub 2023 Jun 17.
7
Discovery and mechanism of action of Thonzonium bromide from an FDA-approved drug library with potent and broad-spectrum inhibitory activity against main proteases of human coronaviruses.
Bioorg Chem. 2023 Jan;130:106264. doi: 10.1016/j.bioorg.2022.106264. Epub 2022 Nov 9.
8
Label-free Sensing of Main Protease Activity of SARS-CoV-2 with an Aerolysin Nanopore.
Chem Asian J. 2022 Nov 2;17(21):e202200747. doi: 10.1002/asia.202200747. Epub 2022 Sep 20.
9
Fullerenes against COVID-19: Repurposing C and C to Clog the Active Site of SARS-CoV-2 Protease.
Molecules. 2022 Mar 16;27(6):1916. doi: 10.3390/molecules27061916.
10
Colorimetric and Electrochemical Methods for the Detection of SARS-CoV-2 Main Protease by Peptide-Triggered Assembly of Gold Nanoparticles.
Molecules. 2022 Jan 18;27(3):615. doi: 10.3390/molecules27030615.
本文引用的文献
1
Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen.
ACS Pharmacol Transl Sci. 2021 Mar 11;4(3):1096-1110. doi: 10.1021/acsptsci.0c00216. eCollection 2021 Jun 11.
2
A cyclic peptide inhibitor of the SARS-CoV-2 main protease.
Eur J Med Chem. 2021 Oct 5;221:113530. doi: 10.1016/j.ejmech.2021.113530. Epub 2021 May 5.
3
X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease.
Science. 2021 May 7;372(6542):642-646. doi: 10.1126/science.abf7945. Epub 2021 Apr 2.
4
Pre-clustering data sets using cluster4x improves the signal-to-noise ratio of high-throughput crystallography drug-screening analysis.
Acta Crystallogr D Struct Biol. 2020 Nov 1;76(Pt 11):1134-1144. doi: 10.1107/S2059798320012619. Epub 2020 Oct 16.
5
Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease.
Nat Commun. 2020 Oct 7;11(1):5047. doi: 10.1038/s41467-020-18709-w.
6
3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
Sci Transl Med. 2020 Aug 19;12(557). doi: 10.1126/scitranslmed.abc5332. Epub 2020 Aug 3.
7
Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing.
Nature. 2020 Oct;586(7827):113-119. doi: 10.1038/s41586-020-2577-1. Epub 2020 Jul 24.
8
Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease.
Cell Res. 2020 Aug;30(8):678-692. doi: 10.1038/s41422-020-0356-z. Epub 2020 Jun 15.
9
The sprint to solve coronavirus protein structures - and disarm them with drugs.
Nature. 2020 May;581(7808):252-255. doi: 10.1038/d41586-020-01444-z.
10
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.
Science. 2020 Jun 19;368(6497):1331-1335. doi: 10.1126/science.abb4489. Epub 2020 Apr 22.
Zotero 插件